IDEAYA Biosciences, Inc. (IDYA) vs Xenon Pharmaceuticals Inc. (XENE)
A side-by-side comparison of IDEAYA Biosciences, Inc. and Xenon Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IDYA
IDEAYA Biosciences, Inc.
$36.45HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
XENE
Xenon Pharmaceuticals Inc.
$36.35HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — IDYA vs XENE
growth of $100 · dividends reinvested · last 7yIDYA +240.1% (+19.1%/yr)XENE +285.3% (+21.3%/yr)XENE compounded faster over this window
IDYA XENE
IDYA vs XENE: by the numbers
- •XENE is the larger company ($3.51B vs $3.47B market cap).
- •Both run net losses; IDYA's is the smaller (-74.75% vs -4612.13% net margin).
Metrics side by side
Valuation
| Metric | IDYA | XENE |
|---|---|---|
| P/S ratio | 14.80 | N/A |
| P/B ratio | 2.89 | 2.83 |
Profitability
| Metric | IDYA | XENE |
|---|---|---|
| Gross margin | -43.89% | 66.09% |
| Operating margin | -72.84% | -4974.27% |
| Net margin | -74.75% | -4612.13% |
| ROE | -14.60% | -32.94% |
| ROIC | -17.68% | -35.27% |
Growth (annualized)
| Metric | IDYA | XENE |
|---|---|---|
| Revenue CAGR (5Y) | 45.80% | N/A |
| Total return CAGR (5Y) | 7.32% | 4.61% |
Frequently asked
- How have IDYA and XENE total returns compared?
- Over the past 5 years, IDYA delivered 7.32% and XENE delivered 4.61% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
IDEAYA Biosciences ROEXenon Pharmaceuticals ROEIDEAYA Biosciences operating marginXenon Pharmaceuticals operating marginIDEAYA Biosciences revenue growthXenon Pharmaceuticals revenue growthIDEAYA Biosciences free cash flowXenon Pharmaceuticals free cash flow
IDEAYA Biosciences & Xenon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.